Literature DB >> 26639971

Gene Expression Profiling in the APP/PS1KI Mouse Model of Familial Alzheimer's Disease.

Robert Weissmann1, Melanie Hüttenrauch2, Tim Kacprowski3, Yvonne Bouter2, Laurent Pradier4, Thomas A Bayer2, Andreas W Kuss1, Oliver Wirths2.   

Abstract

Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by early intraneuronal amyloid-β (Aβ) accumulation, extracellular deposition of Aβ peptides, and intracellular hyperphosphorylated tau aggregates. These lesions cause dendritic and synaptic alterations and induce an inflammatory response in the diseased brain. Although the neuropathological characteristics of AD have been known for decades, the molecular mechanisms causing the disease are still under investigation. Studying gene expression changes in postmortem AD brain tissue can yield new insights into the molecular disease mechanisms. To that end, one can employ transgenic AD mouse models and the next-generation sequencing technology. In this study, a whole-brain transcriptome analysis was carried out using the well-characterized APP/PS1KI mouse model for AD. These mice display a robust phenotype reflected by working memory deficits at 6 months of age, a significant neuron loss in a variety of brain areas including the CA1 region of the hippocampus and a severe amyloid pathology. Based on deep sequencing, differentially expressed genes (DEGs) between 6-month-old WT or PS1KI and APP/PS1KI were identified and verified by qRT-PCR. Compared to WT mice, 250 DEGs were found in APP/PS1KI mice, while 186 DEGs could be found compared to PS1KI control mice. Most of the DEGs were upregulated in APP/PS1KI mice and belong to either inflammation-associated pathways or lysosomal activation, which is likely due to the robust intraneuronal accumulation of Aβ in this mouse model. Our comprehensive brain transcriptome study further highlights APP/PS1KI mice as a valuable model for AD, covering molecular inflammatory and immune responses.

Entities:  

Keywords:  Alzheimer’s disease; amyloid; differential gene expression; next-generation sequencing; transcriptome; transgenic mice

Mesh:

Substances:

Year:  2016        PMID: 26639971     DOI: 10.3233/JAD-150745

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  3 in total

1.  Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer's disease.

Authors:  Freyja Aichholzer; Hans-Wolfgang Klafki; Isabella Ogorek; Jonathan Vogelgsang; Jens Wiltfang; Norbert Scherbaum; Sascha Weggen; Oliver Wirths
Journal:  Alzheimers Res Ther       Date:  2021-05-04       Impact factor: 6.982

2.  Glycoprotein NMB: a novel Alzheimer's disease associated marker expressed in a subset of activated microglia.

Authors:  Melanie Hüttenrauch; Isabella Ogorek; Hans Klafki; Markus Otto; Christine Stadelmann; Sascha Weggen; Jens Wiltfang; Oliver Wirths
Journal:  Acta Neuropathol Commun       Date:  2018-10-19       Impact factor: 7.801

3.  Alzheimer's Disease Mouse as a Model of Testis Degeneration.

Authors:  Vince Szegeczki; Gabriella Horváth; Helga Perényi; Andrea Tamás; Zsolt Radák; Dóra Ábrahám; Róza Zákány; Dora Reglodi; Tamás Juhász
Journal:  Int J Mol Sci       Date:  2020-08-10       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.